AXA Private Equity Carves Out Rhodia's Aspirin Unit

Law360, New York (November 2, 2011, 2:36 PM EDT) -- AXA Private Equity, the international buyout arm of French insurer AXA Group, has acquired Rhodia SA's aspirin and salicylic acid unit through a pharmaceutical subsidiary to build its chemical holdings, the firm said Wednesday.

The carved-out units will become Novacyl, a new company within Novacap, the chemical conglomerate AXA bought from Boston-based private equity firm Bain Capital LLC earlier this year. AXA said Novacyl will have annual revenues of €100 million ($137 million), making it the world's biggest producer of aspirin and salicylic acid, which are...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.